Megestrol acetate
- Generic Name
- Megestrol acetate
- Brand Names
- Megace
- Drug Type
- Small Molecule
- Chemical Formula
- C24H32O4
- CAS Number
- 595-33-5
- Unique Ingredient Identifier
- TJ2M0FR8ES
- Background
17-Hydroxy-6-methylpregna-3,6-diene-3,20-dione. A progestational hormone used most commonly as the acetate ester. As the acetate, it is more potent than progesterone both as a progestagen and as an ovulation inhibitor. It has also been used in the palliative treatment of breast cancer.
- Indication
For the treatment of anorexia, cachexia, or an unexplained, significant weight loss in patients with a diagnosis of acquired immunodeficiency syndrome (AIDS). Also used for the palliative management of recurrent, inoperable, or metastatic breast cancer, endometrial cancer, and prostate cancer in Canada and some other countries.
- Associated Conditions
- Anorexia, Cachexia, Inoperable Carcinoma of Breast, Inoperable Endometrial Carcinoma, Metastatic Breast Carcinoma, Recurrent Breast Carcinoma, Recurrent Endometrial Carcinoma, Significant, Unexplained Weight Loss, Metastatic Endometrial carcinoma
- Associated Therapies
- Palliative Treatment
Testing the Addition of the AKT Inhibitor, Ipatasertib, to Treatment With the Hormonal Agent Megestrol Acetate for Recurrent or Metastatic Endometrial Cancers
- Conditions
- Interventions
- First Posted Date
- 2022-09-14
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 96
- Registration Number
- NCT05538897
- Locations
- 🇺🇸
Summa Health System - Akron Campus, Akron, Ohio, United States
🇺🇸Banner University Medical Center - Tucson, Tucson, Arizona, United States
🇺🇸University of Arizona Cancer Center-North Campus, Tucson, Arizona, United States
A Pilot Study on Fertility Conservative Treatment of Atypical Endometrial Hyperplasia in Singapore
- Conditions
- Interventions
- First Posted Date
- 2022-08-08
- Last Posted Date
- 2022-08-08
- Lead Sponsor
- KK Women's and Children's Hospital
- Target Recruit Count
- 60
- Registration Number
- NCT05492487
- Locations
- 🇸🇬
Singapore General Hospital, Singapore, Singapore
🇸🇬National University Hospital, Singapore, Singapore
🇸🇬KK Women's and Children's Hospital, Singapore, Singapore
Mirtazapine Versus Megestrol Acetate in Treatment of Anorexia-cachexia in Advanced Cancer Patients.
- First Posted Date
- 2022-05-18
- Last Posted Date
- 2022-05-18
- Target Recruit Count
- 80
- Registration Number
- NCT05380479
- Locations
- 🇧🇩
Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
Study of Megestrol Acetate in Grade 2 Endometrioid Endometrial Cancer
- First Posted Date
- 2022-04-18
- Last Posted Date
- 2023-11-03
- Lead Sponsor
- Sunnybrook Health Sciences Centre
- Target Recruit Count
- 5
- Registration Number
- NCT05332483
- Locations
- 🇨🇦
Sunnybrook Health Sciences, Toronto, Ontario, Canada
Refining Adjuvant Treatment in Endometrial Cancer Based on Molecular Features
- First Posted Date
- 2022-02-24
- Last Posted Date
- 2024-11-28
- Lead Sponsor
- Leiden University Medical Center
- Target Recruit Count
- 1615
- Registration Number
- NCT05255653
- Locations
- 🇨🇦
The POLEmut-BLUE trial: Princess Margaret Cancer Centre, University of Toronto, Toronto, Canada
🇳🇱Medisch Spectrum Twente, Enschede, Netherlands
🇳🇱The MMRd-GREEN trial: Leiden University Medical Center, Leiden, Netherlands
Olanzapine Versus Megestrol Acetate for the Treatment of Loss of Appetite Among Advanced Cancer Patients
- Conditions
- Interventions
- First Posted Date
- 2021-06-25
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 360
- Registration Number
- NCT04939090
- Locations
- 🇺🇸
Missouri Baptist Sullivan Hospital, Sullivan, Missouri, United States
🇺🇸BJC Outpatient Center at Sunset Hills, Sunset Hills, Missouri, United States
🇺🇸Billings Clinic Cancer Center, Billings, Montana, United States
Levonorgestrel-Releasing Intrauterine System (LNG-IUS) in the Management of Atypical Endometrial Hyperplasia
- Conditions
- Interventions
- First Posted Date
- 2021-05-21
- Last Posted Date
- 2023-07-05
- Lead Sponsor
- Wake Forest University Health Sciences
- Registration Number
- NCT04897217
Metformin Plus Megestrol Acetate as a Fertility-sparing Treatment in Patients With Atypical Endometrial Hyperplasia
- Conditions
- Interventions
- First Posted Date
- 2020-10-29
- Last Posted Date
- 2022-04-05
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 12
- Registration Number
- NCT04607252
- Locations
- 🇨🇳
Obstetrics and Gynecology Hospital, Fudan University, Shanghai, Shanghai, China
Megestrol Acetate Compared With Megestrol Acetate and Metformin to Prevent Endometrial Cancer
- First Posted Date
- 2020-10-06
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 50
- Registration Number
- NCT04576104
- Locations
- 🇺🇸
Cedars Sinai Medical Center, Los Angeles, California, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Duke University Medical Center, Durham, North Carolina, United States
Megestrol Acetate Plus Rosuvastatin in Young Women With Atypical Endometrial Hyperplasia
- Conditions
- Interventions
- First Posted Date
- 2020-07-29
- Last Posted Date
- 2024-01-29
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 36
- Registration Number
- NCT04491682
- Locations
- 🇨🇳
Obstetrics and Gynecology Hospital, Fudan University, Shanghai, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.